The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/19118 |
Resumo: | COVID-19 is an infectious disease caused by SARS-CoV-2, has a high transmission rate and has resulted in thousands of registered deaths worldwide. Currently, there are no clinical studies proving the effectiveness of specific drugs against SARS-Cov-2. However, previous experiences with similar viruses indicated potential effectiveness for certain drugs, including the use of Hydroxychloroquine (HCQ). At the beginning of the COVID-19 pandemic, the World Health Organization and the Ministry of Health of Brazil guided the use of HCQ as a therapeutic option. However, its role in viral infection by SARS-CoV-2, in addition to its real benefits in vivo, was unknown. Therefore, the aim of this study was to conduct a literature review on the use of HCQ in cases of COVID-19, and to discuss the results found in studies that performed in vitro and in vivo tests, in order to investigate its therapeutic efficacy. The review was carried out using descriptors in a computerized database. The antiviral efficacy of HCQ against SARS-CoV-2 in vitro has been described by several authors, inhibiting virus replication and mediating cytokine storm through its immunomodulatory effects. However, in vivo analyzes in complex organisms showed no effect on reducing viral load, as well as no clinical benefit to the patient. Thus, although preliminary in vitro results have shown to be positive and promising, evidence from randomized clinical trials indicated that HCQ did not cause the same effects in vivo against COVID-19. |
id |
UNIFEI_c9133ddbc8e8d21c73e5822c0a96d6ba |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/19118 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review studyEl uso de Hidroxicloroquina durante la pandemia de COVID-19: un estudio de revisión de la literaturaO uso da Hidroxicloroquina no decorrer da pandemia da COVID-19: um estudo de revisão bibliográficaCOVID-19SARS-CoV-2Hydroxychloroquine.COVID-19SARS-CoV-2Hidroxicloroquina.COVID-19SARS-CoV-2Hidroxicloroquina.COVID-19 is an infectious disease caused by SARS-CoV-2, has a high transmission rate and has resulted in thousands of registered deaths worldwide. Currently, there are no clinical studies proving the effectiveness of specific drugs against SARS-Cov-2. However, previous experiences with similar viruses indicated potential effectiveness for certain drugs, including the use of Hydroxychloroquine (HCQ). At the beginning of the COVID-19 pandemic, the World Health Organization and the Ministry of Health of Brazil guided the use of HCQ as a therapeutic option. However, its role in viral infection by SARS-CoV-2, in addition to its real benefits in vivo, was unknown. Therefore, the aim of this study was to conduct a literature review on the use of HCQ in cases of COVID-19, and to discuss the results found in studies that performed in vitro and in vivo tests, in order to investigate its therapeutic efficacy. The review was carried out using descriptors in a computerized database. The antiviral efficacy of HCQ against SARS-CoV-2 in vitro has been described by several authors, inhibiting virus replication and mediating cytokine storm through its immunomodulatory effects. However, in vivo analyzes in complex organisms showed no effect on reducing viral load, as well as no clinical benefit to the patient. Thus, although preliminary in vitro results have shown to be positive and promising, evidence from randomized clinical trials indicated that HCQ did not cause the same effects in vivo against COVID-19. COVID-19 es una enfermedad infecciosa causada por el SARS-CoV-2, tiene una alta tasa de transmisión y ha provocado miles de muertes registradas en todo el mundo. Actualmente, no hay estudios clínicos que demuestren la efectividad de medicamentos específicos contra el SARS-Cov-2. Sin embargo, experiencias previas con virus similares indicaron una potencial efectividad de ciertos medicamentos, incluido el uso de hidroxicloroquina (HCQ). Al comienzo de la pandemia de COVID-19, la Organización Mundial de la Salud y el Ministerio de Salud del Brazil orientaron el uso de HCQ como opción terapéutica. Sin embargo, se desconocía su papel en la infección viral por SARS-CoV-2, además de sus beneficios reales in vivo. Por lo tanto, el objetivo de este estudio fue realizar una revisión de la literatura sobre el uso de HCQ en casos de COVID-19, y discutir los resultados encontrados en estudios que realizaron pruebas in vitro e in vivo, con el fin de investigar su eficacia terapéutica. La revisión se realizó mediante descriptores en una base de datos informatizada. Varios autores han descrito la eficacia antiviral de la HCQ contra el SARS-CoV-2 in vitro, inhibiendo la replicación del virus y mediando la tormenta de citocinas a través de sus efectos inmunomoduladores. Sin embargo, los análisis in vivo en organismos complejos no mostraron ningún efecto sobre la reducción de la carga viral, así como ningún beneficio clínico para el paciente. Por lo tanto, aunque los resultados preliminares in vitro han demostrado ser positivos y prometedores, la evidencia de los ensayos clínicos aleatorios indicó que el HCQ no causó los mismos efectos in vivo contra COVID-19. A COVID-19 é uma doença infecciosa causada pelo SARS-CoV-2, apresenta elevada taxa de transmissão e têm resultado em milhares de óbitos registrados em todo o mundo. Atualmente, ainda não existem estudos clínicos que comprovem a eficácia de medicamentos específicos contra o SARS-Cov-2. No entanto, experiências anteriores com vírus semelhantes indicaram potencial de efetividade para determinados fármacos, dentre eles, o uso da Hidroxicloroquina (HCQ). No início da pandemia da COVID-19, a Organização Mundial da Saúde e o Ministério da Saúde orientaram a utilização da HCQ como opção terapêutica. No entanto, não se conhecia exatamente o seu papel na infecção viral pelo SARS-CoV-2, além dos seus reais benefícios in vivo. Portanto, o objetivo deste estudo foi realizar uma revisão bibliográfica sobre o uso da HCQ em casos de COVID-19, e discutir os resultados encontrados nos trabalhos que realizaram testes in vitro e in vivo, a fim de investigar a sua eficácia terapêutica. A revisão foi realizada utilizando descritores em base de dados informatizados. A eficácia antiviral da HCQ contra o SARS-CoV-2 in vitro foi descrita por diversos autores, inibindo a replicação do vírus e mediando a tempestade de citocinas por meio de seus efeitos imunomoduladores. No entanto, análises in vivo em organismos complexos não evidenciaram efeito na redução da carga viral, bem como nenhum benefício clínico ao paciente. Desta forma, apesar dos resultados preliminares in vitro terem se mostrado positivos e promissores, as evidências de ensaios clínicos randomizados apontaram que a HCQ não provocou os mesmos efeitos in vivo contra a COVID-19.Research, Society and Development2021-08-15info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1911810.33448/rsd-v10i10.19118Research, Society and Development; Vol. 10 No. 10; e444101019118Research, Society and Development; Vol. 10 Núm. 10; e444101019118Research, Society and Development; v. 10 n. 10; e4441010191182525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/19118/17004Copyright (c) 2021 Amanda Brito Silva; Beatriz Bonfadini de Sá Galbraith; Camila Lopes Rieke Borges; Daniel Pereira de Rezende Sarmento Costa; Danilo Bines; Gabriela Carreiro Kubitschek Lopes; Hannah Barboza Vianna Bekierman; Helena Ferreira Bruzzi Porto; Júlia Moraes de Andrade Seabra; Julia Vieira Santos; Michel Vladimir de Sousa Cabral ; Pedro Henrique Saugo; Victor Gonçalves de Andrade ; Pedro Leite Azevedohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSilva, Amanda BritoGalbraith, Beatriz Bonfadini de Sá Borges, Camila Lopes Rieke Costa, Daniel Pereira de Rezende Sarmento Bines, DaniloLopes, Gabriela Carreiro KubitschekBekierman, Hannah Barboza Vianna Porto, Helena Ferreira Bruzzi Seabra, Júlia Moraes de Andrade Santos, Julia Vieira Cabral , Michel Vladimir de Sousa Saugo, Pedro HenriqueAndrade , Victor Gonçalves de Azevedo, Pedro Leite2021-10-02T21:49:16Zoai:ojs.pkp.sfu.ca:article/19118Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:39:05.507373Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study El uso de Hidroxicloroquina durante la pandemia de COVID-19: un estudio de revisión de la literatura O uso da Hidroxicloroquina no decorrer da pandemia da COVID-19: um estudo de revisão bibliográfica |
title |
The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study |
spellingShingle |
The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study Silva, Amanda Brito COVID-19 SARS-CoV-2 Hydroxychloroquine. COVID-19 SARS-CoV-2 Hidroxicloroquina. COVID-19 SARS-CoV-2 Hidroxicloroquina. |
title_short |
The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study |
title_full |
The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study |
title_fullStr |
The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study |
title_full_unstemmed |
The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study |
title_sort |
The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study |
author |
Silva, Amanda Brito |
author_facet |
Silva, Amanda Brito Galbraith, Beatriz Bonfadini de Sá Borges, Camila Lopes Rieke Costa, Daniel Pereira de Rezende Sarmento Bines, Danilo Lopes, Gabriela Carreiro Kubitschek Bekierman, Hannah Barboza Vianna Porto, Helena Ferreira Bruzzi Seabra, Júlia Moraes de Andrade Santos, Julia Vieira Cabral , Michel Vladimir de Sousa Saugo, Pedro Henrique Andrade , Victor Gonçalves de Azevedo, Pedro Leite |
author_role |
author |
author2 |
Galbraith, Beatriz Bonfadini de Sá Borges, Camila Lopes Rieke Costa, Daniel Pereira de Rezende Sarmento Bines, Danilo Lopes, Gabriela Carreiro Kubitschek Bekierman, Hannah Barboza Vianna Porto, Helena Ferreira Bruzzi Seabra, Júlia Moraes de Andrade Santos, Julia Vieira Cabral , Michel Vladimir de Sousa Saugo, Pedro Henrique Andrade , Victor Gonçalves de Azevedo, Pedro Leite |
author2_role |
author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Silva, Amanda Brito Galbraith, Beatriz Bonfadini de Sá Borges, Camila Lopes Rieke Costa, Daniel Pereira de Rezende Sarmento Bines, Danilo Lopes, Gabriela Carreiro Kubitschek Bekierman, Hannah Barboza Vianna Porto, Helena Ferreira Bruzzi Seabra, Júlia Moraes de Andrade Santos, Julia Vieira Cabral , Michel Vladimir de Sousa Saugo, Pedro Henrique Andrade , Victor Gonçalves de Azevedo, Pedro Leite |
dc.subject.por.fl_str_mv |
COVID-19 SARS-CoV-2 Hydroxychloroquine. COVID-19 SARS-CoV-2 Hidroxicloroquina. COVID-19 SARS-CoV-2 Hidroxicloroquina. |
topic |
COVID-19 SARS-CoV-2 Hydroxychloroquine. COVID-19 SARS-CoV-2 Hidroxicloroquina. COVID-19 SARS-CoV-2 Hidroxicloroquina. |
description |
COVID-19 is an infectious disease caused by SARS-CoV-2, has a high transmission rate and has resulted in thousands of registered deaths worldwide. Currently, there are no clinical studies proving the effectiveness of specific drugs against SARS-Cov-2. However, previous experiences with similar viruses indicated potential effectiveness for certain drugs, including the use of Hydroxychloroquine (HCQ). At the beginning of the COVID-19 pandemic, the World Health Organization and the Ministry of Health of Brazil guided the use of HCQ as a therapeutic option. However, its role in viral infection by SARS-CoV-2, in addition to its real benefits in vivo, was unknown. Therefore, the aim of this study was to conduct a literature review on the use of HCQ in cases of COVID-19, and to discuss the results found in studies that performed in vitro and in vivo tests, in order to investigate its therapeutic efficacy. The review was carried out using descriptors in a computerized database. The antiviral efficacy of HCQ against SARS-CoV-2 in vitro has been described by several authors, inhibiting virus replication and mediating cytokine storm through its immunomodulatory effects. However, in vivo analyzes in complex organisms showed no effect on reducing viral load, as well as no clinical benefit to the patient. Thus, although preliminary in vitro results have shown to be positive and promising, evidence from randomized clinical trials indicated that HCQ did not cause the same effects in vivo against COVID-19. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-08-15 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/19118 10.33448/rsd-v10i10.19118 |
url |
https://rsdjournal.org/index.php/rsd/article/view/19118 |
identifier_str_mv |
10.33448/rsd-v10i10.19118 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/19118/17004 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 10; e444101019118 Research, Society and Development; Vol. 10 Núm. 10; e444101019118 Research, Society and Development; v. 10 n. 10; e444101019118 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052808160083968 |